Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

Entrectinib is a pan-tyrosine-kinase inhibitor that targets oncogenic rearrangements in NTRK, ROS1 and ALK. The combined results of two clinical trials demonstrated the efficacy of entrectinib in ROS1-rearranged NSCLC. Because the development of drug resistance is inevitable, it would be helpful to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ku, Bo Mi, Bae, Yeon Hee, Lee, Kyoung Young, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Preclinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066105/
https://www.ncbi.nlm.nih.gov/pubmed/31124056
http://dx.doi.org/10.1007/s10637-019-00795-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066105/
https://www.ncbi.nlm.nih.gov/pubmed/31124056
http://dx.doi.org/10.1007/s10637-019-00795-3

Ejemplares similares